Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNED: Adjuvant Nivolumab or Nivolumab plus Ipilimumab in Stage IV Melanoma (NED)
NCT02523313Phase 2Completed
- Start
- Sep 2015
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in Malignant Melanoma (MM). Started Sep 2015; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT02523313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02523313.